Citigroup’s Aktis Oncology AKTS Stock Holding History

Citigroup’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$425K	Buy	13,177 +12,158	+1,193%	+$250K	﹤0.01%	3981
2026 Q1	$18.2K	Buy	+1,019	New	+$19.8K	﹤0.01%	4856

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Citigroup's AKTS Position: Q2 2026 in Review

Citigroup increased its Aktis Oncology (AKTS) stake by 1,193% in Q2 2026, buying an estimated $250K and bringing the position to 13,177 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #3981.

Citigroup first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

Citigroup held 13,177 shares of Aktis Oncology worth $425K as of Q2 2026.
Citigroup bought 12,158 Aktis Oncology shares in Q2 2026, an estimated $250K.
Aktis Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3981 holding.
Citigroup first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.